TRAX Company Profile and Key Details

First Tracks Biotherapeutics Inc last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $6.45. This means the shares are trading above this model’s fair value.

Our AI price prediction model suggests that First Tracks Biotherapeutics Inc stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -14.86%, with price expected at $17.13 by July 13, 2026, within a range of $16.21 to $18.07 3-Month Outlook: Projected fall of -97.66%, reaching $0.47 by September 25, 2026, with a range of $0.27 to $0.65. 1-Year Outlook: Projected gain of 1178.28%, with price at $257.19 by June 29, 2027, within a range of $257.01 to $257.43.

Valuation shows First Tracks Biotherapeutics Inc trading at a premium to the broader market with a P/E of -6.97. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $30.00, suggesting 49.11% upside. Our AI forecast model points to short-term weakness (-14.86% over two weeks), a medium-term fall (-97.66% over three months), and a longer-term gain (1178.28% over one year), with expected trading ranges indicating moderate volatility.

First Tracks Biotherapeutics Inc (NASDAQ:TRAX) closed at $20.12 USD, gaining $3.11 (18.28%) from the previous close of $17.01. The stock is currently mid-range between its 52-week high and low $14.72 and $26.80. With a market capitalization of about $702.03 million, First Tracks Biotherapeutics Inc is classified as a small-cap and shows lower-than-market volatility (beta ~0.00). Key stats such as the average daily volume over the past year has been around 484.86 thousand shares, trading with heavier-than-usual volume. Headquartered in San Diego, CA, First Tracks Biotherapeutics Inc operates in the Healthcare sector and the Biotechnology industry. Led by CEO Daniel R. Faga, the company employs approximately 104 people and listed since April 20, 2026. First Tracks Biotherapeutics, Inc., situated in San Diego, California, specializes in pioneering new immunology-based treatments.

First Tracks Biotherapeutics Inc trades at a P/E ratio of -6.97, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 2.64 suggesting the stock is closer to book value. The P/FCF stands at -8.8, also below market averages.